Search

everythinglearnresearchcommunity

for

Search:↓

Dauricine may help treat certain brain cancers by reducing cancer cell growth and promoting cell death.

Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.

Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.

Tofacitinib can cause skin eruptions similar to palmoplantar pustulosis.

Researchers identified promising inhibitors for the BRD4 protein, including finasteride and amentoflavone.

PROTACs show promise in cancer treatment by effectively degrading specific harmful proteins.

A man with a rare skin condition and a new gene mutation developed high calcium levels due to his treatment.

JAK inhibitors show promise in treating difficult skin diseases.

A man's severe skin reaction from cancer treatment improved with early diagnosis and proper medication.

Janus kinase inhibitors are effective for severe alopecia areata, promoting hair regrowth.

Blocking mTORC1 activity with rapamycin could help increase hair pigmentation and growth, potentially reversing gray hair.

Oral tofacitinib effectively treats alopecia areata long-term with manageable side effects.

Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.

Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.

Tofacitinib successfully treated vitiligo in a patient with lupus without side effects.

Oral and topical tofacitinib can help regrow hair in people with severe alopecia areata.

Patients were very satisfied with hair regrowth after taking ritlecitinib for alopecia areata.

Hedgehog pathway inhibitors can treat certain aggressive cancers but face limitations like resistance and side effects.

Baricitinib is generally safe for long-term use in treating severe alopecia areata.

TICE salvage chemotherapy is effective for treating germ-cell tumors with poor prognosis.

ONO-3403 effectively reduces mouse skin tumor growth without side effects.

Oral tofacitinib significantly improves lichen planopilaris symptoms without adverse effects.

Sacituzumab govitecan is effective but has side effects like hair loss and diarrhea in treating metastatic triple-negative breast cancer.

Targeted anticancer therapies often cause skin issues, affecting treatment adherence and quality of life.

TYK2 inhibition may help treat alopecia areata by promoting hair growth and reducing immune response.

No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.

Blocking the Hedgehog pathway may help overcome drug resistance in multiple myeloma.

Ritlecitinib is generally safe for alopecia areata patients over 72 months.

Topical ruxolitinib failed to regrow hair in a 66-year-old with alopecia areata.

Medicaid coverage for alopecia areata treatments is inconsistent and often limited.